Skip to main content
Erschienen in: Breast Cancer 4/2020

29.02.2020 | Original Article

Self-reported cognitive decline in Japanese patients with breast cancer treated with endocrine therapy

verfasst von: Sena Yamamoto, Eiko Masutani, Harue Arao

Erschienen in: Breast Cancer | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Despite contributing to the control of hormone receptor-positive breast cancer, a highly prevalent cancer type, endocrine therapy affects patients’ cognitive function. We aimed to identify cognitive decline following the start of endocrine therapy using patient-reported measures and investigate factors associated with cognitive difficulties.

Methods

This cross-sectional survey used a self-administered, anonymous questionnaire. The participants were 876 patients with breast cancer who experienced subjective cognitive difficulties after starting endocrine therapy. Our sample was recruited from 11 patient advocacy groups, 5 clinics, and 2 hospitals in Japan. The questionnaire assessed subjective cognitive difficulties (30 items), psychological well-being, demographic and clinical information, and other subjective symptoms.

Results

Of 510 (58.2%) responses, we analyzed 405 (46.2%) questionnaires. Exploratory factor analysis identified three factors of cognitive difficulties: Factor 1, “difficulties in manipulating memory and language;” Factor 2, “difficulties in processing multiple pieces of information;” and Factor 3, “difficulties in maintaining attention and concentration.” Factor 1 was the most common type, and it was significantly related to the treatment characteristics of endocrine therapy. Multivariate logistic regression analysis revealed that fewer household members, a history of breast surgery, more severe menopausal symptoms, and greater psychological distress were significantly associated with cognitive difficulties. As cognitive difficulties increased, the proportion of participants suspected to have psychological disorders increased significantly.

Conclusions

Patients treated with endocrine therapy for breast cancer experience intricately intertwined impairments in several domains of cognitive function. They have an increased risk of psychological disorders corresponding to the degree of subjective cognitive function.
Literatur
17.
Zurück zum Zitat Nakagawa Y, Daibo I. Manual of the Japanese version of the General health questionnaire. Tokyo: Nihon Bunka kagakusha (in Japanese); 1985. Nakagawa Y, Daibo I. Manual of the Japanese version of the General health questionnaire. Tokyo: Nihon Bunka kagakusha (in Japanese); 1985.
19.
Zurück zum Zitat Doi Y, Minowa M (2003) Factor structure of the 12-item general health questionnaire in the Japanese general adult population. Psychiatry Clin Neurosci 57:379-83. doi: 10.1046/j.1440-1819.2003.01135.x. Doi Y, Minowa M (2003) Factor structure of the 12-item general health questionnaire in the Japanese general adult population. Psychiatry Clin Neurosci 57:379-83. doi: 10.1046/j.1440-1819.2003.01135.x.
20.
Zurück zum Zitat Abe T, KKSI MT (1996) Kupperman Kohnenki Shogai index. Kuppahman-Kohnenki-Shohgai-Shisuh, Abe-henpoh. Shiyoh-tebiki. Sankyoboh, Kyoto (in Japanese). Abe T, KKSI MT (1996) Kupperman Kohnenki Shogai index. Kuppahman-Kohnenki-Shohgai-Shisuh, Abe-henpoh. Shiyoh-tebiki. Sankyoboh, Kyoto (in Japanese).
Metadaten
Titel
Self-reported cognitive decline in Japanese patients with breast cancer treated with endocrine therapy
verfasst von
Sena Yamamoto
Eiko Masutani
Harue Arao
Publikationsdatum
29.02.2020
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 4/2020
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-020-01062-7

Weitere Artikel der Ausgabe 4/2020

Breast Cancer 4/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.